Sign in

VERTEX PHARMACEUTICALS INC / MA

VRTX

Share price not shown yet: live market data is not connected. Everything below comes from VRTX’s own SEC filings.

View options chain →

Fundamentals

SEC filings

Ratios that need a share price (P/E, PEG, P/S, dividend yield) are not shown yet, because live market data is not connected. Everything below comes from filed financials.

Rule of 40
40%
rev growth + FCF margin
Revenue growth
+10.2%
TTM vs prior TTM
FCF margin
30.2%
ROE (TTM)
23.5%
TTM NI ÷ avg equity
Net debt
—
total debt − cash & ST inv.
Dilution (YoY)
-1.1%
negative = buybacks
SBC / revenue
5.5%
TTM revenue
$12.6B

Revenue

$0B$1B$2B$3BDec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’26$3B

EPS (diluted)

$-15.00$-10.00$-5.00$0.00$5.00Dec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’26$4.31

Margins

GrossOperating
-150%-100%-50%0%50%100%Dec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’2685%

Net income

-$3B-$2B-$1B$0B$1BDec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’26$1B

Net margin

-150%-100%-50%0%50%Dec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’2633%

Free cash flow vs. stock-based comp

FCFSBC
-$4B-$3B-$2B-$1B$0B$1BDec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’26$1B

Operating cash flow vs. capex

OCFCapex
-$4B-$2B$0BDec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’26$1B

R&D vs. SG&A

R&DSG&A
$0.0B$0.2B$0.4B$0.6B$0.8B$1.0BDec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’26$1.0B

Insider activity

SEC Form 4
Reading Form 4 filings from SEC EDGAR…